- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03731962
Using Preprocedural Urine NMR(Nuclear Magnetic Resonance) -Based Metabolomics Analysis
Using Preprocedural Urine NMR-Based Metabolomics Analysis to Prediction the Risk of Contrast Induced Nephropathy Following Elective Coronary Angiography
The use of coronary intervention has increased over the last decade. Contrast induced nephropathy (CIN) that develops as a result of procedures using intravenous or intra arterial contrast enhancement, or other diagnostic procedures, has been reported to be the third leading cause of acute renal failure in hospitalized patients. It has been hypothesized that this occurs as a result of direct toxicity, oxidative stress, and ischemic injury. Numerous studies have evaluated the incidence of CIN in patients undergoing angiography. There are limited studies in the acute care setting. Therefore, a tool that could identify early risk factors for CIN would be valuable for patient care.
Metabolomic profiling is the identification of small molecule metabolites that are altered in response to injury. We hypothetize that urine metabolomic profiles may differ in patients before and after contrast administration coronary intervention.We hypothesized that metabolomic profiles will differ between those patients who develop CIN and those who do not after contrast administration. In addition we believe that metabolomics profiles prior to angiography may identify subjects who will go on to develop CIN and are therefore at higher risk.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The specific aim of this pilot study is to determine if metabolomics profiles differ in patients who develop CIN after contrast administration for coronary angiography versus those who do not. Additionally, our goal was to identify specific urinary metabolites that warrant further investigation.This is a pilot study of prospectively identified patients undergoing a coronary intervention with intraarterial contrast during their evaluation. The study was approved by the University of Shahid Beheshti, Medical institutional review boards.
100 number of patients were enrolled. To be eligible for the study, patients had to be >18 years old, undergoing coronary angiography and have at least 1 of the following high risk features for CIN: diabetes, coronary artery disease, congestive heart failure. Past medical history was confirmed by chart review if available, or patient report.
Patients were excluded from the study if they had an estimated glomerular filtration rate <15 mL/min/1.73 m2, a history of organ transplantation, were currently on immunosuppressive medications, were septic or on antibiotic therapy, had a history of or were currently receiving dialysis of any type, had an exposure to iodinated contrast within 3 days prior to the study, or had multiple doses of contrast given.
Patients were managed according to the treating provider recommendations. No intervention was requested as part of this study. There was no institutional standard for mandatory fluid administration or use of N-acetylcysteine prior to elective coronary angiography.All patients received approximately 60 mili Liter of intravenous iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
data were collected prospectively after patients were identified as fulfilling inclusion and exclusion criteria, and informed consent was obtained. Data collection included , demographics, dietary history, medical history, physical examination, and electrocardiogram findings, as documented by the treating emergency physician. Medical history was confirmed through patient self-report and review of the medical record when available. Medications administered before arrival were also recorded. No additional laboratory tests were mandated as a part of the trial study and the treating physician ordered all tests, except urinary metabolomics analysis, according to their clinical judgment. Urine samples were collected as a midstream sample or via a foley bag prior to angiography and 12 hours post imaging. Samples were aliquoted into 2 mL samples and frozen at -80˚C.
Serum creatinine levels were recorded at presentation, and at 24 and 72 hours. The outcome measure was the presence CIN, which was defined as an increase in serum creatinine level of ≥0.5 mg/dL above baseline within 72 hours after contrast administration.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tehran, Iran, Islamic Republic of
- Nooshin Dalili
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients had to be >18 years old Undergoing elective coronary angiography
Exclusion Criteria:
- estimated glomerular filtration rate <15 mL/min/1.73 m2
- history of organ transplantation
- using immunosuppressive medications
- septic patients or on antibiotic therapy
- a history of receiving dialysis of any type
- an exposure to iodinated contrast within 3 days prior to the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Developed Contrast Induced Nephropathy
Coronary Angiography
|
All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
|
OTHER: Without CIN
Coronary Angiography
|
All patients received approximately 60 mL of intra arterial iodinated contrast material that was administered via computer-controlled automated power injector at 4 mL per second.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
developing CIN
Time Frame: within 48 hours after contrast administration
|
an increase in serum creatinine level of ≥0.5 mg/dL above baseline within 48 hours after contrast administration
|
within 48 hours after contrast administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urine Metabolomics
Time Frame: within 48 hours after contrast administration
|
Finding differences between urine metabolites profile between patients develop CIN and without CIN
|
within 48 hours after contrast administration
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dalili, Shahid Beheshti University of Medical Sciences
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBMU23567/J
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contrast-induced Nephropathy
-
Singapore General HospitalActive, not recruitingContrast-induced NephropathySingapore
-
Chinese PLA General HospitalUnknownContrast-induced NephropathyChina
-
Memorial University of NewfoundlandUniversity of AlbertaWithdrawnContrast Induced NephropathyCanada
-
Sun Yat-sen UniversityCompletedContrast Induced NephropathyChina
-
Isfahan University of Medical SciencesUnknownContrast-Induced NephropathyIran, Islamic Republic of
-
Noura gamalNot yet recruitingContrast-induced Nephropathy
-
CardioRenal Systems, Inc.Active, not recruitingContrast Induced NephropathyUnited States
-
rabab ahmed mohamedCairo UniversityCompletedContrast-induced Nephropathy
-
Assiut UniversityUnknownContrast-induced Nephropathy
-
Isfahan University of Medical SciencesCompletedContrast-Induced NephropathyIran, Islamic Republic of
Clinical Trials on Coronary Angiography
-
Institute for Clinical Evaluative SciencesCompleted
-
University Hospital of PatrasCompletedCoronary Artery Bypass SurgeryGreece
-
St. Olavs HospitalNorwegian University of Science and Technology; Helse Nord-Trøndelag HF; Alesund... and other collaboratorsRecruitingNon-ST Elevated Myocardial InfarctionNorway
-
Hospital San Carlos, MadridHospital General Universitario Gregorio Marañon; Hospital Clinic of Barcelona; Germans Trias i Pujol Hospital and other collaboratorsCompleted
-
Chinese Academy of Medical Sciences, Fuwai HospitalUnknownNon-ST Elevation Myocardial InfarctionChina
-
Antwerp Cardiovascular Institute MiddelheimCompletedCoronary Artery DiseaseBelgium
-
University Hospital Schleswig-HolsteinDeutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)CompletedOut-of-hospital Cardiac ArrestGermany
-
General Hospital of Chinese Armed Police ForcesCompletedCoronary Artery DiseaseChina
-
Assiut UniversityCompleted
-
Rennes University HospitalCompleted